SecBot SecBot
PRESS-RELEASE ·Filed May 30, 2026

BNTX

BioNTech SE
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

The robust efficacy across PD-L1 subgroups and manageable safety profile de-risk pumitamig's Phase 3 program. Monitor upcoming data from Phase 3 trials (ROSETTA Lung-02, Lung-201, Lung-202) and potential regulatory filings. The partnership with BMS provides strong commercial infrastructure. Near-term catalyst: further Phase 3 readouts in NSCLC and other indications.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$91.70
T+0 close · May 30, 2026 · via day close
Latest settled
+24.37%
T+60 · $114.05
Vs SPY
+23.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $91.70entry
  2. T+1 · 6mo ago −2.79%α −2.94% · $89.14
  3. T+5 · 5mo ago −3.95%α −1.20% · $88.08
  4. T+20 · 5mo ago +1.47%α +2.77% · $93.05
  5. T+60 · 3mo ago +24.37%α +23.14% · $114.05

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech and BMS announced positive interim Phase 2 data for pumitamig (PD-L1xVEGF bispecific) plus chemotherapy in first-line NSCLC at ASCO 2026. The data showed high confirmed objective response rates (cORR) of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower dose, with 100% disease control rate and manageable safety. This supports the ongoing Phase 3 program and positions pumitamig as a potential new standard of care across PD-L1 expression levels.

Key Facts

  • Interim Phase 2 data from ROSETTA Lung-02 trial (NCT06712316) presented at ASCO 2026
  • cORR of 63.6% in non-squamous and 72.7% in squamous NSCLC at the lower 1400 mg dose
  • 100% disease control rate (DCR) across all evaluable patients
  • cORR by PD-L1 expression: 47.6% (TPS <1%), 77.8% (TPS 1-49%), 100% (TPS ≥50%)
  • Grade ≥3 treatment-related adverse events in 48.8% of patients; pumitamig-related in 23.3%
  • Treatment discontinuation due to AEs in 4 patients (9.3%)
  • Phase 3 part of ROSETTA Lung-02 actively enrolling; two additional global Phase 3 trials in NSCLC ongoing
  • Seven global Phase 3 trials with registrational potential currently ongoing across multiple indications

Financial Impact

No financial figures provided; clinical data supports potential multi-billion-dollar peak sales opportunity if approved in first-line NSCLC, a large market (~85% of lung cancer cases)

revenuepipeline value

Risk Factors

  • Phase 3 trials may fail to replicate Phase 2 efficacy or show unexpected safety signals
  • Competition from existing PD-(L)1 inhibitors and other bispecifics in development
  • Regulatory approval not guaranteed; manufacturing and commercial execution risks

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3303897

Track record

38 reports on BNTX

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 30, 2026